Life Sciences Archive » November, 2023

Life Sciences - November, 2023

306 articles

• DeSantis, Newsom Square Off Over Healthcare In Fox Debate
• Pfizer Overhyped Its COVID-19 Vax Efficacy, Texas AG Claims
• IP Forecast: Beauty And The Copyright-Protected Beast
• SEC Waives $40M Fine For Mallinckrodt In Medicaid Scheme
• Premera Launches Fresh Takeda Antitrust Suit Over IBS Drug
• Sorrento Gets OK For 5-Month Ch. 11 Wind-Down
• Ex-Devos CEO Must Pay $103M Over Drug Refund Scheme
• Invisalign Customers Get Class Certification In Antitrust Suits
• Clinics Sue To Block Wash. AG 'Abortion Pill Reversal' Probe
• Ohio Panel Won't Hold Drug Testing Co. Liable For Fatal Crash
• Drug Cabinet Finger Scans Are BIPA-Exempt, Ill. Justices Say
• FDA Shares New Info To Help Carry Out Food Traceability Rule
• FDA Promotes Chief Scientist To Deputy Commissioner
• What Lawyers Must Know About Calif. State Bar's AI Guidance
• Industry Must Elevate Native American Women Attys' Stories
• The Fed. Circ. In Nov.: Factual Support And Appellate Standing
• 11th Circ. Orders New Trial In Pill Mill Row Over Ruan
• Justices Told PTAB's Ax Of Ventilator Patent Was Wrong Call
• Republican AGs Assail Abortion Coverage Law At 9th Circ.
• Wachtell Lipton Guiding AbbVie On $10.1B ImmunoGen Buy
• Fed. Circ. Told To Defer To ITC In Apple Watch IP Row
• House Told AI Is A Tool, Not A Decision Maker, In Health Care
• Investors Say Co. Lied About Ultrasound Tech Prior To Merger
• Eli Lilly Partners With Prism BioLab In Deal Worth $660M
• New York Electric Utility Escapes Insurer's $3.7M Lab Fire Suit
• Pharma Co. Says 'Ulterior' Aim Shouldn't Kill Records Suit
• White House Activity Is A Band-Aid For Regulating AI In Health
• Drug Giants Face 3rd RICO Suit In 3 Weeks Over Insulin Prices
• How New Expert-Witness Rules Put Science Front And Center
• AbbVie Tells 3rd Circ. 'Sham' Case Ruling 'Explodes' Privilege
• Understanding Discovery Obligations In Era Of Generative AI
• Insurers Escape Allergy Treatment Groups' Antitrust Claims
• Biotech Co.'s Counterclaims Against Ex-Exec Trimmed
• UCLA Study Finds Calif. Teens Can't Get Plan B At Pharmacies
• Drugmakers Argue Double Patenting Ruling Defies Congress
• Group Says Doctor COVID-19 Disinformation Suit Isn't Moot
• Mich. Health Dept. Asks 6th Circ. To Back Baby Blood Program
• Daiichi Awarded $46M Fees In Cancer Drug Patent Arbitration
• Sanctioned Wholesaler Wants Abbott Labs Out Of Her Trust
• Rep. Eshoo On Retiring: 'Health Care Has Been My North Star'
• USPTO Wants Antibody Patent Case Sent Back For Review
• Fajr Capital-Led Consortium Paying $1B For Aster's Gulf Biz
• Sens. Question Anesthesia Co.'s 'Monopolistic' Model
• Law Firm Leaders Cautiously Optimistic Heading Into 2024
• The 2023 Law360 Pulse Leaderboard
• Bristol Myers Strikes Up To $2.3B Avidity Cardio Partnership
• Levi, Pomerantz Seek To Lead Insulin Pump Co. Investor Suit
• Amicus Groups Tell High Court To End Chevron Deference
• HHS' OIG Finds Low Risk Of Misuse For Opioid Treatment Drug
• Regeneron False Claims Act Case Paused Amid Appeal
• PTAB Denies Review Of Univ. Of Texas System Cancer Patent
• Arthrex Gets PTAB To Strike Down More P Tech Patents
• Teva, Eli Lilly Call Off Infringement Suit Over Migraine Drug
• Longhorn Vaccines Urges Vidal To Ax PTAB Sanctions Order
• FDA Quits Global Med Device Regulatory Group
• Kochava Ruling May Hint At Next Privacy Class Action Wave
• Forecasting The Impact Of High Court Debit Card Rule Case
• Indian Glycine Co.'s Waffling Justifies Penalty Duties
• Holdouts In Alexion Insider Trading Case Get May Trial Date
• ESG Around The World: Mexico
• Pharma Cos. Taking Discovery Disputes To Alabama Judge
• Nurse Practitioner Pleads Guilty To $4M Medical Scheme
• FDA And Companies Must Move Quickly On Drug Recalls
• Catching Up With Delaware's Chancery Court
• Dems' Victory Lap: Michigan's Biggest Legislation Of 2023
• Full Fed. Circ. Warned Of Fallout From Double Patenting Case
• FDA Rule Calls For 'Dual' Sharing Of Side Effects In TV Ads
• Debevoise Attys On AI Potential In Health, 'Iterative' Mistakes
• FDA Resource Latest Move To Prevent Baby Formula Scarcity
• COVID Tolling Fight Splits Mich. Judges, Spurs 'Histrionics'
• Pharma Co.'s Complaint Is Over Nonexistent Recall, FDA Says
• IPO Market Still Kicking As End Of 2023 Draws Near
• Bioverativ Class Seeks Sanctions For Insiders' Trades
• The Case For Post-Bar Clerk Training Programs At Law Firms
• LG Chem Hit With NC Suit Over 'Exploding' E-Cigarette Battery
• Mifepristone Ruling Risks 'Profound Disruption,' Justices Told
• Would Ending Chevron Deference Really Make Waves?
• FTC, Calif. Hit Ancestry Co. Over Deceptive Marketing, Billing
• AbbVie Says Rivals' Rinvoq Generics Infringe 34 Patents
• Alcon's $1.2M Sanctions Fee Bid For Its MoFo Attys Slashed
• FTC Warns Of Harms In Mylan Dispute With Sanofi
• Dermatology Drug Developer Can Tap $3M Of Ch. 11 Loan
• Chinese Drug Co. Wants J&J Conspiracy Claim Tossed
• Purdue Fight Over PTAB Delay Came Too Late, Fed. Circ. Says
• Chickasaw Seek Movement From Optum In Rx Payback Suit
• Allergy Testing Co. Head Charged In $5.9M Fraud Scheme
• A Telecom Attorney's Defense Of The Chevron Doctrine
• Baltimore Merck Vax Suit Proceeds But Utah, Idaho Claims Cut
• What's At Stake In Bystolic 'Side Deals' Litigation
• PE Firm, Anesthesia Practice Ask To Toss FTC Antitrust Case
• Amyris Woos 16 Bidders For Consumer Brands, Nears Auction
• Drug Giants Face New Racketeering Suit Over Insulin Prices
• 2 HHS Warnings Highlight Anti-Kickback Risks For Physicians
• Ex-Aegerion Rep Cops To Fraud, Avoiding Trial Redo
• Attorneys Have An Ethical Duty To Protect The Judiciary
• Attys Want $4.2M In Fees For Aurora Health Privacy Case
• Eli Lilly Gets ITC To Launch Probe Into Diabetes Drug Imports
• DEA Public Disclosure Process 'Kafka Like,' Texas Atty Claims
• Takeda Escapes Antitrust Suit Over IBS Drug
• Merck Buying Caraway Therapeutics For Up To $610M
• ITC Says Apple Goes 'Too Far' In AliveCor Smartwatch Dispute
• Cross-Market Implications In FTC's Anesthesia Complaint
• Colo. Says 11th Amendment Shields It From Teva EpiPen Suit
• SEC 'Shadow Trading' Case Survives Exec's Early Win Bid
• Invisalign Antitrust Classes Win Some, Lose Some On Cert.
• Ousted HR Exec Claims Life Sciences Co. Fired Her For Age
• Pharma Co. RevitaLid Approved For Ch. 11 Equity Swap Plan
• Drugmaker Tells NC Court Director Took Trade Secrets To Rival
• Catching Up With Delaware's Chancery Court
• USPTO's Vidal Sends Denied Biotech IPR To Review Panel
• Dermatology Drug Developer Hits Ch. 11 With Sale Plan
• Taylor English Defeats Bid To Revive Malpractice Claim In Ga.
• 'Immature Sniping' Sparks Sanctions Threat In Humana Spat
• Del. Jury Says NanoString Owes $31M In 10x Patent Spat
• FDA's Lack Of Power May Limit FTC's Patent Challenge
• Judge Won't Delay Ruling If States Can Join Abortion Pill Suit
• AmerisourceBergen Escapes Investor Drug-Dregs Suit In Del.
• 1st Circ. To Review Crucial Issue In Teva, Regeneron Cases
• Chancery Grants Full $18M 'Mootness' Fee To Politan Counsel
• Chancery Refuses Toss Of Biotech Firm Share Award Suit
• Centene Board Got No Red Flags On Pricing, Del. Court Told
• Vidal Revives Sleep Disorder IP Fight For More Fintiv Analysis
• Biotech Co. Will Pay $400K For Bribes, Faces No Prosecution
• Kenvue Should Have Raised FDA Probe Before IPO, Suit Says
• Danaher's $5.7B Abcam Buy Gets The Green Light To Close
• Novartis, Amgen Migraine Drug Worsened Seizures, Suit Says
• Fraud, Abuse Remain Top HHS Challenges, Watchdog Says
• Exact Sciences Launches Patent Suit Over Colon Cancer Test
• Former Acting FDA Commissioner Woodcock To Retire In 2024
• Mask Cos. And Insurer Resolve N95 Coverage Dispute
• 3 Texans Convicted In $145M Health Care Fraud
• Health Care Holding Biz To Go Public Via SPAC Merger
• Feds Drop Price-Fixing Case Against Former Drug Exec
• Vaccine Maker Novavax Appoints New COO, CLO
• Houston 'Pill Mill' Operators Sentenced To Federal Prison
• FTC Orange Book Move Signals New Pharma Patent Scrutiny
• Munger Tolles Beats DQ Bid In GenapSys' Paul Hastings Suit
• AI Can Help Lawyers Overcome The Programming Barrier
• Calif. Prosthetics Co. Says Sales Manager Stole Trade Secrets
• Taxation With Representation: Skadden, Goodwin Procter
• Anti-Abortion Lawmakers Urge Justices To Skip Pill Ruling
• Del. Arbitration Check Ordered For Insys Trustee CEO Claims
• Florida Pharmacy Settles Fraud Claims For $800K
• Judge Orders Utah Dietary Product Maker To Destroy Goods
• Ohio Justices Ask How Saving Abortion Access Affects Ban Bid
• Pharma Compliance Exec Gets 4 Yrs For $50M Medicare Fraud
• How Legal Teams Can Prep For Life Sciences' Tech Revolution
• Judge Says Breast Milk TM Dismissal Bid Was Minutes Late
• Fed. Circ. Says Medtronic Can't Revive Patent Challenge
• Illinois Seeks To Rejoin Narcolepsy Drug Overcharge Suit
• Del. Justices Uphold Merck's Post-Bayer Sale Talc Liability
• Alexion Investors Want $31M Atty Fee In Sales Tactics Deal
• FDA Warns Shops Over E-Cig Items Allegedly Aimed At Kids
• Cancer Drug Co. Says Efficacy Talk Didn't Mislead Investors
• Arnold & Porter Adds Ex-Assistant US Atty From Foley Hoag
• 3 Men Sentenced To Jail In $54M Drug Kickback Scheme
• Post-AIA Patents Cleared To Ignore 2015 Prior Art Precedent
• Ariz. Co. Banned From Making Unapproved Contraceptives
• 3 States Slam Feds' Request For Pause In Abortion Drug Suit
• Insurer Says Amryis' Ch. 11 Plan Missing Info On $800K Bonds
• Bausch Health Hit With $75M Suit Alleging Botched Drug Deal
• Medical Services Co. Sues Chase Over Defamatory 'Blacklist'
• Biopharmaceutical Co. To Go Public Via All-Stock Merger
• Union Health Care Plans File Antitrust Action Against Takeda
• Preparing Law Students For A New, AI-Assisted Legal World
• Seattle Startup Wins $83M In IP Spat With Silicon Valley Rival
• Siemens Paying $2.3B As Part Of India Energy Restructuring
• Judge Grants Eli Lilly Injunction In Mounjaro Trademark Case
• Del. Judge OKs Bidding Procedures In Zymergen Ch. 11
• 7 Women Join Texas Suit To Clarify Scope Of Abortion Ban
• Texas Judge Defers Ch. 11 Rulings Pending Recusal Hearing
• Express Scripts Wants Class Bid Cut In Acthar Case
• House Members Eye Bringing Psychedelic Treatment To Vets
• Apple Blasted For Pausing IP Cases 'Over A Hundred Times'
• Cannabis Patent Case Trimmed, Gene Pool Tells Court
• 6th Circ. Won't DQ Special Master Over 'Reply-All' Email
• ESG Around The World: South Korea
• General Counsel Need Data Literacy To Keep Up With AI
• BXP, Norges Close Boston Science Lab Deal At $1.7B Value
• Florida Duo Cops To $1.5M Medicare Fraud In Ga. Court
• PostMeds Slapped With Another Suit Over Data Breach
• House Rules Committee Tussles Over HHS Funding Bill
• Jill Biden To Steer New Women's Health Research Initiative
• Korean Device Maker Scores $1.7M Win Against Conn. Co.
• Polsinelli Bolsters Public Policy Practice With 2 Hires
• Worker Says Washington Managers Liable For Shorting Wages
• Ice Miller Guides Ohio Co.'s $620M Sale To Japanese Biotech
• Med Supplier Aeroflow Wins Fees From 'Unreasonable' IP Row
• USPTO Urges Supreme Court To Deny Fintiv Review
• Catching Up With Delaware's Chancery Court
• Bradley Arant Adds Ex-McDermott Atty To Health Care Team
• Novartis Can't Dodge Sales Rep.'s Gender Bias Suit
• Ex-Aegerion Rep. Strikes Deal To Avoid 2nd Fraud Trial
• Justices Pass On Nurses' Challenge To NJ Vaccine Mandate  
• Paul Clement's Big Idea: Overrule Chevron, Ease Polarization
• Novo's Suit Over Compounded Weight-Loss Drug Is Tossed
• AARP, Others Bash AstraZeneca's Drug Pricing Challenge
• Senators Told That AI Is Already Harming Patients
• Latham, Cooley Lead Cargo Therapeutics $281M IPO
• Drug Lab Brass Face Investor Suit Over DOJ Primate Probe
• Point Biopharma Investor Sues For Info On Lilly's $1.4B Buy
• Regeneron Hits Rival With Patent Suit Over Eye Med Generic
• Abortion Foes Challenge Voter-Approved Amendment In Mich.
• Trending At The PTAB: Administrative Procedure
• Rite Aid's Reasons For Ch. 11 Go Beyond Opioid Suits
• Deals Rumor Mill: Shein, Siemens, BioMarin
• Repeal Of Mich. Drugmaker Liability Shield Goes To Governor
• Navigating Discovery Of Generative AI Information
• Ohio Jury Finds CR Bard Didn't Reveal Hernia Mesh Risks
• Drug Maker Calls DEA Admin Judge Appointment Flawed
• Nursing Home Co. Loses Some Defenses In False Claims Case
• FDA's Lab-Developed Test Rule May Bring Historic Challenges
• Gilead Wants HIV Drug Antitrust Suit Tossed Again, For Good
• Justices Told To Ignore Group's Take On Abortion Pill OK
• Finding Focus: Strategies For Attorneys With ADHD
• A Look At DOJ's New Nationwide Investment Fraud Approach
• Pharmacies Fight Tribe's Bid To Lift Stay In Payback Dispute
• Naomi Watts Says Amyris Owes Her For Work on Wellness Co.
• McCarter & English Wants $6.8M, Skewers Ex-Client's Words
• EQRx Investor Sues In Del. For Docs On Battered SPAC Deal
• Precigen's $13M Investor Settlement Gets Final Green Light
• Abbott Says It Is Not Implicated In Baby Formula MDL
• Apple Argues AliveCor's PTAB Stay Bid Is Different And Unfair
• Abbott Labs Wants To Ditch Glucerna Class Claims
• AmerisourceBergen Trims But Can't Beat Feds' Opioid Suit
• Ga. Justices Hint Health Agency Decision Exceeded Authority
• 9th Circ. Affirms Ax Of Calif. Glyphosate Cancer Warning Label
• FTC Challenges Asthma Product Patents Listed With FDA
• Fed. Circ. Judge Casts Doubt On Sweetener Enzyme Patents
• Trans Adults, Youth Tell 11th Circ. To Uphold Stay on Fla. Ban
• Amgen Seeks To Toss Investor Claims Of $10B Hidden Tax Bill
• Fed. Circ. Shoots Down Appeal In Eye Drug Patent Fight
• Va. County Alleges Racketeering In Suit Over Insulin Prices
• Senate Confirms Monica Bertagnolli As NIH Director
• Christian Clinic Says New Evidence Shows Standing In Appeal
• The 2023 Law360 Prestige Leaders
• How Law Firms Build And Protect Stellar Reputations
• Ex-Perkins Coie Atty DQ'd From Defending PacBio In IP Fight
• SmileDirectClub Says Invisalign Maker Wants It 'To Disappear'
• HRSA Unlawfully Limited Drug Discount Program, Judge Says
• Drug Discount Program Crosses US Law, Pharma Lobby Says
• AstraZeneca Must Face Sales Reps' Pay Bias Suit
• Ga. Doc To Pay $225K To Settle FCA Suit Over 'Upcoding'
• Texas Balks At HHS Mootness Argument In Abortion Pill Row
• 3 States Ask To Join Suit To Halt Access To Abortion Drug
• Catching Up With Delaware's Chancery Court
• CMS Pushes To Boost Medicare Advantage Competition
• Drug Compounding Co. Sues FDA Over 'Catch-22' Recall Ask
• Walgreens Hit With Investors Suit Over Opioid Epidemic
• Carl Sagan Estate Says Infringer Deleted Evidence On Website
• Earnout Contract Considerations After NC Good Faith Ruling
• Puerto Rico Drug Distributor Fined $12M For Opioid Failures
• Fed. Circ. Gives Viatris 2nd Shot In Actelion Patent Fight
• Winston & Strawn Accused Of Filing 'Duplicative' Pharma Suit
• Bristol-Myers To Buy Orum's Cancer Treatment Program
• FDA's Off-Label Comms Guidance Is A Reluctant Step Forward
• Justices Rebuff Opioid Doctor's Quest For 2nd Round
• Justices Grant Purdue Creditors Separate Argument Time
• Ex-FDA Regulator, J&J Exec Returns To Arnold & Porter In DC
• Gilead Sues To Reclaim Convicted Ex-CFO's $4M Legal Fees
• 'Devil's In The Details' Of Biden's AI Health Plans, Experts Say
• Fla. Lab To Pay $1.2M For Drug Test Referral Kickbacks
• Teva Investors Win Class Cert. In Drug Kickback Suit
• Reata Inks $45M Deal With Investors Over Failed Drug
• DuBois Hit With $2M Contract Verdict But No Infringement
• Abbott Gets Some DexCom Patent Claims Wiped Out
• IP Hires: Bracewell, Proskauer
• ITC Partly Ends Review Of Drug Device Imports
• Judge Says Honeywell Wants Too Much In Early IP Suit
• Pacira Hits Rivals With False Ad Suits Over Pain Drugs
• UK Litigation Roundup: Here's What You Missed In London
• Amazon Targets Counterfeit Brain Supplement Sellers
• Feds Plan $9B In Remedy Payments After Drug Discount Fight
• How Biden's AI Order Stacks Up Against Calif. And G7 Activity
• Reading Between The Lines Of HHS' National Lab Opinion
• Synlab Boards Won't Lean On Whether $1.3B Buyout Is Fair
• ITC Ban On Apple Watch Could Still Be Reversed
• Bradley Arant Atty Exits With No Sanctions Over Her Texting
• Tech Co. To Lose Kilpatrick Attys Over 'Financial Burden'
• J&J Bankruptcy May Spark SCOTUS 'Texas Two-Step' Scrutiny
• Monteverde Seeks $5M In Fees From Oclaro Investor Deal
• Cooley, Paul Hastings Steer Gene Therapy Firm's $100M IPO
• HHS Hits Back At AstraZeneca's Challenge To Drug Price Rule
• Nonprofit Calls For CMS-Amgen Price Talks To Reflect Abuse
• Firms Ask 1st Circ. To Force Ruling In Fee Row After 5 Years
• Medical Gear Co. Whistleblower Mostly Slips Counterclaims
• States Want Generic Drug Price-Fixing Claims Back In Conn.
• Reproductive Health Act Passes Michigan House
• Noteholders Want Biotech Co.'s Ch. 11 Circumstances Probed
• Fla. Abortion Access Ballot 'Hoodwinks' Voters, AG Says
• 25 AGs Want Warning Labels On Oxygen-Reading Devices
• Moderna Blasts Pfizer Bid To Add Defense To Patent Row
• A Closer Look At Proposed HHS Research Misconduct Rule
• Myovant, Sumitomo Call Alleged Skadden Conflict Public Info
• Abbvie Sued In Ill. For Probing Applicants' Medical Histories
• Incontinence Drug Ruling Offers Key Patent Drafting Lessons
• Urologist Sold Defective Penile Implants, Patient Alleges
• AbbVie Bet To Swap Parkinson's Patent Claims Fails At PTAB
• FDA Beats Alvogen Suit Over Xifaxan Skinny Label Rejection
• Acuitas Fights To Keep COVID-19 Biotech IP Suit Alive
• Barnes & Thornburg Adds Environmental Pro In Grand Rapids
• Why Hemp-Synthesized Intoxicants Need Uniform Regs
• Life Sciences Regulators Must Write Cloud-Specific Guidance
• Bradley Arant Atty Accused Of Texting Witnesses Seeks Exit
• Fed. Circ. Elekta Holding May Make Patent Prosecution Harder
• Attorneys, Law Schools Must Adapt To New Era Of Evidence